Q&A: Page 3
Exclusive interviews with industry leaders
-
A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here
Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.
Taren Grom and Meagan Parrish • July 20, 2023 -
Google for genes? This AI company aims to curate the entire human genome.
Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge.
Michael Gibney • July 20, 2023 -
As biologics boom, here’s how manufacturers are keeping up
Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.
Michael Gibney • July 19, 2023 -
A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus
After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.
Alexandra Pecci • July 11, 2023 -
Merck’s New Jersey campus is getting a biotech makeover
With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.
Michael Gibney • July 11, 2023 -
A BMS exec’s journey around the world in 90 days
As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.
Karissa Waddick • July 5, 2023 -
How Sanofi is taking a ‘creative’ approach to dealmaking
Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.
Taren Grom • June 23, 2023 -
DIA’s chief exec is on a mission to grow its footprint across healthcare
Marwan Fathallah came onboard earlier this year to lead the organization into an era of change.
Michael Gibney • June 22, 2023 -
Ranking reveals biopharma’s most innovative companies
IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.
Taren Grom • June 7, 2023 -
How Takeda finds the hottest new science to fuel its oncology work
Takeda's president of the global oncology business unit is always "scanning the horizon" for the partnerships that will drive the next big innovations.
Michael Gibney • June 1, 2023 -
From farm to pharma: How cows could play a role in the next flu breakthrough
SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.
Alexandra Pecci • May 16, 2023 -
AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’
With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.
Taren Grom • May 10, 2023 -
How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science
The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.
Taren Grom • May 5, 2023 -
From science to strategy, this exec is painting Genmab’s bigger picture into the next decade
Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.
Michael Gibney • May 2, 2023 -
A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient
The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.
Taren Grom • May 1, 2023 -
5 minutes with — DTRA’s Dr. Amir Kalali
An industry veteran, innovator and curator, Dr. Amir Kalali discusses the high points of his career and his go-to productivity hack.
Taren Grom • April 28, 2023 -
Cure Ventures has $350M to pour deep into biotech ‘company building’
The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.
Michael Gibney • April 20, 2023 -
Depression has long been treated chronically — Sage wants to change that
Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.
Michael Gibney • April 18, 2023 -
5 minutes with — Genlantis Diagnostics’ Ahsan Awan
A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”
Taren Grom • April 14, 2023 -
5 minutes with — Parexel’s Peyton Howell
The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."
Taren Grom • April 7, 2023 -
Amgen’s aim for a ‘moonshot’ in cardiovascular disease
A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.
Taren Grom • April 5, 2023 -
Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork
Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.
Michael Gibney • March 30, 2023 -
This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once
The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.
Michael Gibney • March 23, 2023 -
Babson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
Kelly Bilodeau • March 13, 2023 -
IQVIA’s OG of data analytics on the latest clinical trial trends
IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.
Taren Grom • March 10, 2023